Xeris Biopharma Holdings, Inc. 8K

Xeris Biopharma reported strong Q2 2026 revenue growth and tightened 2026 guidance, eliminated its 2028 convertible notes via exchanges and conversions, and expanded patent protection for Keveyis and XP‑8121 while incurring a one‑time non‑cash loss tied to the note exchanges.

On August 6, 2026, Xeris Biopharma Holdings, Inc. reported its financial results for the quarter and six months ended June 30, 2026, highlighting a 34% year-over-year increase in net product revenue to $91.0 million driven primarily by Recorlev, improvement in gross margin to 86%, and tightened full‑year 2026 total revenue guidance to $385–$390 million, while also disclosing a GAAP net loss of $31.1 million for the quarter largely due to a one‑time, non‑cash ~$31 million charge related to the exchange of its 8.00% Convertible Senior Notes due 2028. The company detailed exchange and conversion agreements executed June 11, 2026 and settled in July 2026 that eliminated all remaining 2028 Convertible Notes through a mix of $23.0 million in cash and issuance of approximately 8.6 million shares of common stock, resulting in no 2028 Convertible Notes outstanding. Xeris also announced receiving a USPTO Notice of Allowance for a new Keveyis patent expected to extend intellectual property protection through at least 2039 and the grant of a second U.S. patent for its XP‑8121 hypothyroidism candidate, along with updated Adjusted EBITDA metrics (Q2 2026 Adjusted EBITDA of $19.3 million and year‑to‑date of $34.4 million), balance sheet data showing $121.7 million in cash and cash equivalents, and upcoming investor events including an XP‑8121 Phase 3 program webinar and participation in healthcare conferences.

Filing Facts

CIK

1867096

Ticker

XERS

Form

8K

Source Type

fda

Accession

0001867096-26-000063

Alert Tier

7